Lars Fruergaard Jørgensen, Novo Nordisk CEO (Chris Ratcliffe/Bloomberg via Getty Images)
Novo Nordisk continues diabetes, obesity sales rise, but still on the back foot with Wegovy supply
As demand for Novo Nordisk’s GLP-1 products continues unabated, all eyes are on the pharma giant to meet demand.
Starting this month, Novo has more …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
